Normocalcemic primary hyperparathyroidism: one-year follow-up in one hundred postmenopausal women.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

27 citing papers in PubMed.

1. Effects of alendronate and vitamin D in patients with normocalcemic primary hyperparathyroidism.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2015
   Trial
2. Normocalcemic hyperparathyroidism and hypoparathyroidism in two community-based nonreferral populations.The Journal of clinical endocrinology and metabolism · 2013
   Trial
3. Osteoporosis and Normocalcemic Primary Hyperparathyroidism (Conservatively or Surgically Managed).Journal of clinical medicine · 2024
   Review
4. Biochemical characteristics and clinical manifestation of normocalcemic primary hyperparathyroidism.Endocrine · 2024
   Article
5. Natural history and complications of normocalcemic hyperparathyroidism: a retrospective cohort study.JBMR plus · 2024
   Article
6. The Eucalcemic Patient With Elevated Parathyroid Hormone Levels.Journal of the Endocrine Society · 2023
   Article
7. Surgery for primary hyperparathyroidism.Archives of endocrinology and metabolism · 2022
   Review
8. Normocalcemic primary hyperparathyroidism.Archives of endocrinology and metabolism · 2022
   Review
9. Comparisons Between Normocalcemic Primary Hyperparathyroidism and Typical Primary Hyperparathyroidism.Journal of Korean medical science · 2022
   Article
10. Normocalcemic Primary Hyperparathyroidism: Need for a Standardized Clinical Approach.Endocrinology and metabolism (Seoul, Korea) · 2021
    Review
11. Normocalcemic Hyperparathyroidism: A Heterogeneous Disorder Often Misdiagnosed?JBMR plus · 2020
    Review
12. Effects of PTH and PTH Hypersecretion on Bone: a Clinical Perspective.Current osteoporosis reports · 2020
    Review
13. Normocalcemic Hyperparathyroidism: Study of its Prevalence and Natural History.The Journal of clinical endocrinology and metabolism · 2020
    Article
14. A clinical perspective of parathyroid hormone related hypercalcaemia.Reviews in endocrine & metabolic disorders · 2020
    Review
15. Current opinions on nephrolithiasis associated with primary hyperparathyroidism.Urolithiasis · 2018
    Review
16. Is parathyroidectomy safe and effective in patients with normocalcemic primary hyperparathyroidism?Langenbeck's archives of surgery · 2018
    Article
17. Classic Primary Hyperparathyroidism Versus Normocalcemic and Normohormonal Variants: Do They Really Differ?World journal of surgery · 2018
    Article
18. Normocalcaemic primary hyperparathyroidism: a diagnostic and therapeutic algorithm.Langenbeck's archives of surgery · 2017
    Review
19. Primary Hyperparathyroidism.F1000Research · 2016
    Review
20. Parathyroid hormone reflects adiposity and cardiometabolic indices but not bone density in normal men.BoneKEy reports · 2016
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as